Neurogene Inc
NGNE
View Detailed Chart
17.230USD
+0.860+5.25%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
254.58MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+5.25%
5 Days
-2.43%
1 Month
-5.85%
6 Months
-19.07%
Year to Date
-16.36%
1 Year
-26.05%
View Detailed Chart
TradingKey Stock Score of Neurogene Inc
Currency: USD Updated: 2026-02-06Key Insights
Neurogene Inc's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 73 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 59.00.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Neurogene Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Neurogene Inc Highlights
StrengthsRisks
Neurogene Inc. is a clinical-stage biotechnology company. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is in development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. It is also developing NGN-101 for the treatment of CLN5 Batten disease.
Growing
The company is in a growing phase, with the latest annual income totaling USD 925.00K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 925.00K.
Fairly Valued
The company’s latest PE is -4.20, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 16.38M shares, decreasing 12.93% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 845.00 shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.48.
Analyst Rating
Based on
6
analysts
Strong Buy
Current Rating
59.000
Target Price
+260.42%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Neurogene Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Neurogene Inc Info
Neurogene Inc. is a clinical-stage biotechnology company. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is in development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. It is also developing NGN-101 for the treatment of CLN5 Batten disease.
Ticker SymbolNGNE
CompanyNeurogene Inc
CEOMcMinn (Rachel L)
Websitehttps://www.neurogene.com/
Related Instruments
+3.66%
+3.17%
+0.93%
+1.99%
+1.78%
+1.60%
-0.95%
+4.49%
+2.10%
+10.00%
+2.72%
+4.15%
+1.81%
+4.17%
+0.72%
+1.06%
+2.46%
0.00%
+0.53%
+0.56%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
69187.800
-782.330 (-1.12%)
282.580
+22.390 (+8.61%)
2042.420
-9.310 (-0.45%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
